Our science

Throughout 13 years of Selvita operations, we’ve had the opportunity to execute a variety of exciting and complex projects for our Clients.
The nature of our business is based on high degree of trust and confidentiality, however we are always very excited to co-author or contribute to scientific publications which present our work.

Whenever possible we publish and present materials such as journal publications, posters, case studies or technical notes, aiming to show the scope of experience of our scientific team.
In the section below, you can find the continuously updated information on our recent publications.

Our science

Blog

Go to blog

Case studies

More case studies

Webinars

Webinar: Screening in drug discovery best practices: past, present, and future
Rob Young
Rob Young Principal Blue Burgundy
Mateusz Biernacki
Mateusz Biernacki Head of HTS Selvita
Tomasz Fraczek
Tomasz Fraczek Senior Scientist Selvita
Tom Coulter
Tom Coulter Integrated Drug Discovery Director Selvita

The initiation of a small molecule drug discovery project invariably involves the identification of potential small-molecule start points from which we must develop novel advanced proprietary compounds that are safe, stable, and active in vivo. The road to these drug candidates is paved with challenges so how can we best navigate hit finding to ensure that we prepare for entry to lead optimization by identifying better hits, more rapidly? How might this provide impact on reduced attrition and more efficiently lead to superior drug candidates?
This webinar is moderated by Tom Coulter (Integrated Drug Discovery Director) and is delivered by Rob Young (Blue Burgundy and ex-GSK), Tomasz Fraczek (Senior Scientist, Selvita), and Mateusz Biernacki (Head of HTS, Selvita).

The webinar will:

  • Incorporate discussion of the background to HTS and other popular screening approaches.
  • Visit current thinking on hit identification.
  • Then consider future technological opportunities and working practices which together will enhance the process of finding high quality hits and leads.
Duration 1 Hour Starting on the October 12, 2021, 16:00 UTC
Drug Discovery
    Ardigen webinar – AI methods in small molecule design
    Michał Warchoł, PhD
    Michał Warchoł, PhD Executive Vice President, General Director of Biomedical Imaging Unit
    Krzysztof Rataj, PhD
    Krzysztof Rataj, PhD Cheminformatics Expert
    Tom Coulter, PhD
    Tom Coulter, PhD Integrated Drug Discovery Director
    Steve Price, PhD
    Steve Price, PhD VP Chemistry and DMPK
    View webinar

      The link has been sent to the e-mail address.

      Ardigen, a part of Selvita Group, organized a live webinar “AI methods in small molecule design”. The event took take place on Tuesday, June 15, 2021, at 04:00 PM CEST and was be held by experts from three companies from Selvita Group - Ardigen (Dr. Michał Warchoł and Dr. Krzysztof Rataj), Selvita (Dr. Tom Coulter), and Fidelta (Dr. Steve Price).

      They presented and discussed various methods of AI application in drug design: the current state-of-the-art AI models for small molecules, which protein properties can be predicted and how to generate new molecules for your project.

      Duration 1 hour Date 16:00, 15 June 2021
      In Vivo Pharmacology
        Fidelta Webinar - Immunopathology and preclinical modelling of systemic lupus erythematosus (SLE)
        Anamarija Markota, PhD
        Anamarija Markota, PhD Team Leader In Vivo Pharmacology
        View webinar

          The link has been sent to the e-mail address.
          Download presentation

            The download link has been sent to the e-mail address.

            Systemic lupus erythematosus (SLE) is a chronic and relapsing, autoimmune disease characterized by a break-down of self-tolerance that leads to tissue inflammation and multiorgan damage. Mouse models of lupus are not only an indispensable tool for studying lupus immunopathogenesis but also serve as a powerful system for fast screening of new SLE treatments in order to evaluate their safety and efficacy prior to clinical trials. Due to the extensive heterogenicity of clinical manifestations of SLE in humans, each mouse model displays only specific attributes of the human lupus phenotype. The webinar gives an insight into the most commonly used mouse models of SLE, highlighting their similarities and differences and discussing the advantages of using one model over the other and tailoring it for specific needs in preclinical research in the context of our current understanding of the immunopathogenesis of SLE.

            Duration 1:00 Date 15:00, 10 June 2021
            Regulatory Services
              Analytical outlook for biosimilar development
              Magdalena Bielak-Łakomska
              Magdalena Bielak-Łakomska Associate Director in Analytics
              Jan Smagur
              Jan Smagur Director of Cell and Molecular Biology Laboratory
              Krzysztof Stawujak
              Krzysztof Stawujak Business Development Manager
              View webinar

                The link has been sent to the e-mail address.
                Download presentation

                  The download link has been sent to the e-mail address.

                  The variability and complexity of biological medicines compel extensive and comprehensive characterization studies to ensure safety and efficacy. Compared to small-molecule drugs, structural and functional characterization of biologics can be a tedious and challenging process. It involves using state-of-the-art technologies to evaluate the purity, specificity, potency, and toxicity, all in accordance with international regulatory guidelines. During the webinar, Selvita’s Experts intend to characterize regulatory requirements and provide an outlook for analytical approaches for biosimilar development and manufacturing process changes.

                  The webinar features a discussion between some of Selvita’s most experienced scientific team members: Magdalena Bielak-Łakomska, Associate Director in Analytics, and Jan Smagur, Director of Cell and Molecular Biology Laboratory, moderated by Krzysztof Stawujak, Business Development Manager.

                  Duration 1:00 Date 15:00, 29 April 2021
                  Drug Discovery
                    A discussion on modern small molecule drug discovery
                    Tom Coulter, PhD
                    Tom Coulter, PhD Integrated Drug Discovery Director
                    Przemyslaw Zawadzki, PhD
                    Przemyslaw Zawadzki, PhD Director of Medicinal Chemistry
                    Piotr Graczyk, PhD
                    Piotr Graczyk, PhD Scientific Director
                    Anna Karawajczyk, PhD
                    Anna Karawajczyk, PhD Head of Computational Chemistry
                    View webinar

                      The link has been sent to the e-mail address.

                      This webinar features a discussion between some of Selvita’s most experienced scientific team members, on selecting small molecule modalities to address protein targets in drug discovery. The debate highlights areas of experience and recommendations for planning approaches for new projects. Dr. Anna Karawajczyk, Head of Computational Chemistry, moderates a discussion of Dr. Tom Coulter, Integrated Drug Discovery Director, Dr. Przemyslaw Zawadzki, Director of Medicinal Chemistry and Dr. Piotr Graczyk, Scientific Director.

                      Duration 1 hour Date 16:00, 03 February 2021

                      Presentations

                      Go to presentations

                      Poster presentations

                      Poster icon
                      Photomediated Synthesis of α,α-Difluoroalcohols poster
                      Download presentation

                        The download link has been sent to the e-mail address.
                        Poster icon
                        LC/HRMS ORBITRAP Technique - Essential tool in drug development process
                        Download presentation

                          The download link has been sent to the e-mail address.
                          Poster icon
                          Cloning and Expression Platform for Production of Recombinant Proteins
                          The poster describes the cost and time-effective Selvita platform for cloning and E. coli expression (which is only one of our platforms for expression).
                          Download presentation

                            The download link has been sent to the e-mail address.
                            Go to poster presentations

                            Publications

                            Poster icon
                            Mitogenic activity and proliferative effect of a New-developed short acting Insulin analogue Human insulin analogues with modified amino acid sequence may exert stronger proliferative effect and carcinogenic potential than insulin itself. The objective of the study was to assess mitogenic activity and activation of proliferation in tumorigenic and non-tumorigenic cell lines upon stimulation with a new-developed short-acting B28Lys-B29Pro human insulin (KP) in comparison to EU Pharmacopeia human insulin standard (HIS) and insulin AspB10 with strong mitogenic, cancerogenic activity. Find out more
                            Go to publications

                            Technical notes

                            In vitro Metabolism
                            Background

                            Drug metabolism includes a wide range of biochemical processes, which finally lead to either drug inactivation or drug transformation, which facilitates the elimination of xenobiotics from the human body.

                            Drugs can be metabolized in different organs, such as intestines, kidneys, spleen, lungs, however, for the large majority of pharmaceutical drug metabolism occurs in the liver.
                            Therefore, assessment of in vitro intrinsic clearance or identification of metabolites formed is crucial at an early stage of the drug discovery process.

                            In vitro…

                            Find out more
                            Go to technical notes

                            Contact form

                              According to the Regulation 2016/679 of the European Parliament and the Council (EU) of 27 April 2016 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data, and repealing Directive 95/46/EC (General Data Protection Regulation; "GDPR"), we hereby inform you that Your personal data will be processed by Selvita S.A. and the companies operating within the Selvita Capital Group in order to present You the Selvita Newsletter. Your personal data are processed in connection with Newsletter subscription and in order to keep You informed about all events taking place in Selvita Capital Group.

                              We guarantee full transparency of the data processing and compliance with all the rights referred to in GDPR, i.e. the right of access, rectification and deletion of data, limiting data processing, the right to transfer, the right to raise objection against processing. Notwithstanding the above, You have the right to submit a complaint to the supervisory authority. Your personal data are not being subject to automated decision-making, including profiling. Your personal data are provided on the voluntary basis, however please be informed that lack of consent results in inability to provide You the Newsletter by Selvita Group. Your data will be processed for the duration of your consent, unless your consent to the processing of your personal data is revoked. Your consent may be withdrawn at any time by sending a request to the e-mail address: gdpr@selvita.com.

                              For more information on how Selvita handles personal data please visit: Privacy Policy. I hereby express my consent to the processing of my personal data by Selvita S.A. with registered office in Cracow 30-348, Bobrzyńskiego 14 and its affiliated companies in order to receive the Newsletter, information about events organized by the Selvita Capital Group and other information regarding Selvita Group activity in accordance with the Regulation 2016/679 of the European Parliament and the Council (EU) of 27 April 2016 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data, and repealing Directive 95/46/EC (General Data Protection Regulation).